DOCSLIB.ORG

Thi Mongol Multumitur

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thi Mongol Multumitur THI MONGOLUS009739772B2MULTUMITUR (12 ) United States Patent ( 10 ) Patent No. : US 9 , 739 ,772 B2 Ryu et al. ( 45 ) Date of Patent: Aug. 22, 2017 ( 54 ) METHOD OF ANALYZING BINDING (51 ) Int. CI. ASPECT OF MEMBRANE PROTEIN IN A GOIN 33 /554 ( 2006 . 01 ) LIVING CELL GOIN 33 /557 (2006 .01 ) (71 ) Applicant: POSTECH ACADEMY- INDUSTRY (52 ) U . S . CI. FOUNDATION , Gyeongsangbuk - do CPC . .. GOIN 33/ 557 ( 2013 .01 ) ; GOIN 33/ 554 (2013 .01 ) (KR ) (58 ) Field of Classification Search ( 72 ) Inventors : Sung Ho Ryu , Gyeongsangbuk -do None (KR ) ; Dohyeon Kim , Seoul ( KR ) ; Nam See application file for complete search history. Ki Lee , Gyeongsangbuk -do (KR ) ; Dong Kyun Kim , Gyeongsangbuk - do (KR ) ; Soyeon Park , Seoul (KR ) ; Yonghoon ( 56 ) References Cited Kwon , Seoul (KR ) ; Kai Zhou , Gyeongsangbuk - do (KR ) PUBLICATIONS ( 73 ) Assignee : Postech Academy - Industry Stewart et al. Biochem J 1991 vol. 275 , p . 569 - 573. * Foundation , Gyeongsangbuk -Do (KR ) Daumas et al. Biophysical J . 2003 vol. 84 , p . 356 - 366 . * ( * ) Notice : Subject to any disclaimer , the term of this Jin et al . Biophysical J . 2007 vol. 93 , p . 1079 - 1088 . * patent is extended or adjusted under 35 Saxton Biophysical J . 1997 vol. 72, p . 1744 - 1753. * U . S . C . 154 (b ) by 0 days . * cited by examiner (21 ) Appl . No. : 14 / 891 , 555 Primary Examiner — Jacob Cheu (22 ) PCT Filed : May 16 , 2014 (74 ) Attorney , Agent, or Firm — Lathrop & Gage LLP ( 86 ) PCT No . : PCT /KR2014 / 004426 (57 ) ABSTRACT $ 371 ( C ) ( 1 ) , ( 2 ) Date : Nov. 16 , 2015 The present invention relates to a method for analyzing the pattern of live intercellular membrane protein binding . The ( 87) PCT Pub . No. : WO2014 /185752 method for analyzing the pattern according to the present invention can analyze accurately , sensitively, quickly , and PCT Pub . Date : Nov . 20 , 2014 readily the binding pattern of a targetmembrane protein and a candidate substance to be specifically bound therewith (65 ) Prior Publication Data without tagging to a ligand , and thus measure directly and US 2016 /0116468 A1 Apr. 28 , 2016 accurately the position and quantitative information of the Related U . S . Application Data binding of the membrane protein and the target substance . Such effects make it possible to apply the method for various (63 ) Continuation of application No . uses such as dissociation constant, mutant study, complex PCT/ KR2013 /011002 , filed on Nov. 29 , 2013 . formation , and signal transduction . Moreover , it is expected to use the method for searching out undiscovered membrane (30 ) Foreign Application Priority Data proteins and target substances . May 16 , 2013 (KR ) .. .. .. .. .. .. .. .. 10 - 2013 -0056008 May 16 , 2014 (KR ) . .. .. .. 10 - 2014 -0059027 19 Claims, 19 Drawing Sheets U . S . Patent Aug . 22, 2017 Sheet 1 of 19 US 9 ,739 , 772 B2 ( FIGM . 1 ] extracellular binding intracellular extracellular rotation total INTERNAL reflection licht intracellular92 . 5 lipid bilayer lioand O membrane protein a fluorescent protein [ FIG . 2 ] cell growth time (cycle ) medium rrrrrrrrr viw imw* voisnuocoefficient 1 2 3 4 coefficientinsinglecell sonrad Condition 1 time ( cycle Multiple temporal uojanjoubur? particle average average mahu wwwwwwwwwwwwwww tracking * ** ** ** * * * ** * ** * * * * ** ** ** * * ** wwwwwwwwwwwwwwwww * * * 1 * total INTEANAL * reflection microscope * diffusion conditioncondition1 24 objective lens coefficient 1 2 3 4 condition 2 time (cycle ) U . S . Patent Aug . 22, 2017 Sheet 2 of 19 US 9 ,739 , 772 B2 [FIG . 3 ] NT Cetuximab WWWWWWWWWWW 4, 300 wwwwwwwwwwwwwwwwwwwwww . * . TV yuniminiminiminnainiminnasPixel( unit) . .. * * . PM Vedete 400 400 14 mwi i 100 iiiiiiiiiii 93 w 400 * * * * * * * * 400 100 400 100 U . S . Patent Aug . 22, 2017 Sheet 3 of 19 US 9 , 739, 772 B2 [FIG . 4 ] PMT - NT PMT- cetuximab . Y W w * -. 4-46 4.47 * . * jasovedecesorios /.% minimi . eritin .conoscino * * ?:1-i; sensori . * . wwwAwwww * series . wwwS wwwwwwwwww diffusioncoefficient .. verter wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww ( cycle ) 2 4 8 10 2 6 8 WWW 10 .4 EGFR - cetuximab * . -* . .'* . * > .concom ??????? * . diffusioncoefficiento .*5 * e * .???????? . .- * www .- * ?????????????????????????????????????????????????????????????????????? . www wird * o i W cetuximab changeindiffusioncoefficient(%) o PMT EGFR U . S . Patent Aug . 22, 2017 Sheet 4 of 19 US 9 ,739 , 772 B2 (FIG . 6 ) 82 - AR G o heterotrimeric Gi protein berperan seperti ADD ribosylated Gi protein pertussis toxin (DTX ) FZD1 per le per [FIG . 7 ] TX changeindiffusioncoefficient(%) marianna mmmmmmm wwwwwwwwwwww wwwwwww om PMT FZD1 B2- AR U . S . Patent Aug . 22, 2017 Sheet 5 of 19 US 9 ,739 , 772 B2 [FIG . 8 ] diffusioncoefficient(um/s) PMT B2- AR EGFR ( FIG . 9 ] changeindiffusioncoefficient(%) e V o batch1 batch2 batch3m1 batch3 - 2 different batches measured on the same day U . S . Patent Aug . 22, 2017 Sheet 6 of 19 US 9 , 739, 772 B2 [FIG . 10 ) WEK293 cell Hela cel .* * changeindiffusioncoefficient(%) changeindiffusioncoefficient(%) * * i nnan AMT EGFR PMT EGFR C2- cc PMT MEGFR & changeindiffusioncoefficient(%) wwwwwwwwwwwwwwwwwwwwwwwwwwwwwww changeindiffusioncoefficient(%) % wwwwwwwwwwwwwwwww $ @ PMT EGFR HEK293 Hela CHO -K1 cell cell cell (FIG . 11Lind] Cetuximab mAb 199 . 12 mab 528 MAL R U . S . Patent Aug. 22 , 2017 Sheet 7 of 19 US 9 , 739, 772 B2 (FIG . 121 retuxlimAb 199 mAb.12 528 MAD R- 1 NT?????? cetuximab?????? W EGF - Gol - Gele - - olin - often PEGFR ( Y1086 ) EGFR Donau miniintindihittiintindihihiiiiiiiii wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww PErk1/ 2 wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwand ?????????. ?? . ?????????? . ?? . ?? . ?????????? . ?? . ???????????? . ?? . ?????????? . ???????? . ?? . ?????????????? . ???????????????????????? . ?? . ?????????? . ?? . ?? . actin wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww wwwww w wwww herenor * PMT 8 WEGFR * * * * changeindiffusioncoefficient(%) @ o cetuximabapp mAb 199 .12 mAb 528 mAbR- 1 U . S . Patent Aug . 22, 2017 Sheet 8 of 19 US 9 , 739, 772 B2 [ FIG . 141 w fluorescent protein EGFR et ErbB2 trastuzumab Cetuximab ( FIG . 151 1 .01 cetuximab *. trastuzumab actin anibody relativeratio(%) immunoglobulin G antibody fluorescence intensity ( arbitrary unit ) U . S . Patent Aug . 22, 2017 Sheet 9 of 19 US 9 ,739 , 772 B2 [FIG . 16 ] PMT 350 3 - EGFRPEST changeindiffusioncoefficient(%) Cetuximab trastuzumab actin antibody (FIG . 17 ] cetuximab Cetuximab Fab2 cetuximab Fab aptamer U . S . Patent Aug . 22, 2017 Sheet 10 of 19 US 9 , 739, 772 B2 [FIG . 18 ] PMT EGFR is * * * * changeindiffusioncoefficient(%) WWWWWWWWWWWWUNNNNNNNNNNN abetöwwwwwwwwwwwwwww when aptamer cetuximab cetuximab Cetuximab [FIG . 19 ] www changeindiffusioncoefficient(%)W Win * * * * * * * w 40 80 120 160 molecular weight (kilodalton ) U . S . Patent Aug . 22, 2017 Sheet 11 of 19 US 9 , 739, 772 B2 [FIG . 20 ] EGFREGFR Dom Icetuximab U . S . Patent Aug . 22, 2017 Sheet 12 of 19 US 9 , 739, 772 B2 [FIG . 21 ] ated cetuximab concentration 1. 0 - - 200. 04. 04 20enthe .06 normalizeddiffusioncoefficient 0 .32 LV wer 0. 64 first measurement 1. 28 second measurement B eatment time point 0 10 20 30 40 time (minute ) U . S . Patent Aug . 22, 2017 Sheet 13 of 19 US 9 , 739, 772 B2 [ FIG . 22] dissociation constant K 0 .62 0 . 19 OM 1 . 0 * wwwwwwwww vojendod693punoq.bewixmajoone qowixnajoojai 01093pun0Q cetuximabunboundEGFR etetter wievi 0 .wwwwwwwwwwwwww 0 0 . 4 0 . 8 wwwww12 ratio of cetuximab - bound EGFA wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww 0 .0 0 . 2 0 . 4 0 .6 0 . 8 1 .0 1. 2 1 . 4 cetuximab (ugimi ) (FIG . 23 ] GFRVIII (mutant ) (EGFRwild type WT ) cetuximab women mAb R - 1 recent U . S . Patent Aug . 22, 2017 Sheet 14 of 19 US 9 , 739, 772 B2 4 ] a cetuximab mAb R - 1 )coefficient(%diffusionchangein 2 o PMT EGFRVIIIwwww [FIG . 25] WA dissociation constant Ko 0 . 36 0 .01 OM 1 . 0 1980 Norway ratioofcetuximab-boundEGFRvIII ratioofCetuximab 18:93punodEGFAVIIIunboundcetuximab 80of . 2 0 . 4 0 .6 0 . 8 1 .0 ratio of cetuximab - BOUND EGFRVII 00 02 04* * * * * * * * * *06 * 08 10* * * * * * * * * * * * * 12* 14 cetuximab (wg /ml ) U . S . Patent Aug . 22, 2017 Sheet 15 of 19 US 9 , 739, 772 B2 (FIG . 26 ] EGER rror 80 -833 - 03 ? } { x } a secondary antibody tertiary antibody (FIG . 27] 5 1. 00 I treatment point www Cetuximab Secondary antibody tertiary normalizeddiffusioncoefficient antibody * * * * ** * * * * * 10 time (minute i ) U . S . Patent Aug . 22, 2017 Sheet 16 of 19 US 9 , 739, 772 B2 [FIG . 28 ) 1. 00 ????????? $ treating point Lappi Cetuximab tertiary antibody y secondary normalizeddiffusioncoefficient antibody wer 0 10 20 time (minute ) [FIG . 29 ) endogenous mese EGFA Fab of EGFA antbody Alexa Fluor 647 14:00 U . S . Patent Aug. 22 , 2017 Sheet 17 of 19 US 9 , 739 ,772 B2 ( FIG . 30 ] fluorescence labeling to mAb done 199 . 12 ( lugim ) www labeling to cetuximab ( Iugem !) fluorescence lebeiing to mab cione 199 . 12 * labeling to cetuximab * cetuximab ( 100ugimi) * cetuximab [100ugimi 10 0 . 81 relativeratio ryyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy relativeratio 0.90 101 102 fluorescence intensity fluorescence intensity (arbitrary unit ) (arbitrary unit ) (FIG . 31] en changeindiffusioncoefficient(%) ene enon !ulingoj?ounww antibody cetuximab U . S . Patent Aug . 22, 2017 Sheet 18 of 19 US 9 , 739, 772 B2 [FIG . 321 immunoglobulin antibody * * Cetuximab (%ijuopuleoouosniDubuaya
Load more

Recommended publications
  • Strategies to Increase ß-Cell Mass Expansion
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Strategies to increase -cell mass expansion Drynda, Robert Lech Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 Strategies to increase β-cell mass expansion A thesis submitted by Robert Drynda For the degree of Doctor of Philosophy from King’s College London Diabetes Research Group Division of Diabetes & Nutritional Sciences Faculty of Life Sciences & Medicine King’s College London 2017 Table of contents Table of contents .................................................................................................
    [Show full text]
  • ILC2 Activation by Protozoan Commensal Microbes
    International Journal of Molecular Sciences Review ILC2 Activation by Protozoan Commensal Microbes Kyle Burrows 1 , Louis Ngai 1 , Flora Wong 1,2, David Won 1 and Arthur Mortha 1,* 1 University of Toronto, Department of Immunology, Toronto, ON M5S 1A8, Canada; [email protected] (K.B.) [email protected] (L.N.); fl[email protected] (F.W.); [email protected] (D.W.) 2 Ranomics, Inc. Toronto, ON M5G 1X5, Canada * Correspondence: [email protected] Received: 3 September 2019; Accepted: 27 September 2019; Published: 30 September 2019 Abstract: Group 2 innate lymphoid cells (ILC2s) are a member of the ILC family and are involved in protective and pathogenic type 2 responses. Recent research has highlighted their involvement in modulating tissue and immune homeostasis during health and disease and has uncovered critical signaling circuits. While interactions of ILC2s with the bacterial microbiome are rather sparse, other microbial members of our microbiome, including helminths and protozoans, reveal new and exciting mechanisms of tissue regulation by ILC2s. Here we summarize the current field on ILC2 activation by the tissue and immune environment and highlight particularly new intriguing pathways of ILC2 regulation by protozoan commensals in the intestinal tract. Keywords: ILC2; protozoa; Trichomonas; Tritrichomonas musculis; mucosal immunity; taste receptors; succinate; intestinal immunity; type 2 immunity; commensals 1. The ILC Lineage 1.1. The Family of Innate Lymphoid Cells Research over the last decade has redirected focus away from classical immune cell interactions within lymphoid tissues towards immunity within non-lymphoid tissues. Within these tissues, immune interactions involve local adaptation and rapid responses by tissue-resident immune cells.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Neural Regulation of Interactions Between Group 2 Innate Lymphoid Cells and Pulmonary Immune Cells
    Prime Archives in Immunology: 2nd Edition Book Chapter Neural Regulation of Interactions between Group 2 Innate Lymphoid Cells and Pulmonary Immune Cells Weiwei Chen1,2, Qiang Shu2 and Jie Fan1,3,4* 1Department of Surgery, University of Pittsburgh School of Medicine, USA 2The Children‟s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, China 3Research and Development, Veterans Affairs Pittsburgh Healthcare System, USA 4McGowan Institute for Regenerative Medicine, University of Pittsburgh, USA *Corresponding Author: Jie Fan, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Published January 18, 2021 This Book Chapter is a republication of an article published by Jie Fan, et al. at Frontiers in Immunology in October 2020. (Chen W, Shu Q and Fan J (2020) Neural Regulation of Interactions Between Group 2 Innate Lymphoid Cells and Pulmonary Immune Cells. Front. Immunol. 11:576929. doi: 10.3389/fimmu.2020.576929) How to cite this book chapter: Weiwei Chen, Qiang Shu, Jie Fan. Neural Regulation of Interactions between Group 2 Innate Lymphoid Cells and Pulmonary Immune Cells. In: Ajmal Khan, Ahmed Al-Harrasi, editors. Prime Archives in Immunology: 2nd Edition. Hyderabad, India: Vide Leaf. 2021. 1 www.videleaf.com Prime Archives in Immunology: 2nd Edition © The Author(s) 2021. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Author Contributions: WC collected the data and drafted the manuscript. WC, QS, and JF conceived and designed the study.
    [Show full text]
  • Guthrie Cdna Resource Center
    cDNA Resource Center cDNA Resource Center Catalog cDNA Resource Center Missouri University of Science and Technology 400 W 11th Rolla, MO 65409 TEL: (573) 341-7610 FAX: (573) 341-7609 EMAIL: [email protected] www.cdna.org September, 2008 1 cDNA Resource Center Visit our web site for product updates 2 cDNA Resource Center The cDNA Resource Center The cDNA Resource Center is a service provided by the faculty of the Department of Biological Sciences of Missouri University of Science and Technology. The purpose of the cDNA Resource Center is to further scientific investigation by providing cDNA clones of human proteins involved in signal transduction processes. This is achieved by providing high quality clones for important signaling proteins in a timely manner. By high quality, we mean that the clones are • Sequence verified • Propagated in a versatile vector useful in bacterial and mammalian systems • Free of extraneous 3' and 5' untranslated regions • Expression verified (in most cases) by coupled in vitro transcription/translation assays • Available in wild-type, epitope-tagged and common mutant forms (e.g., constitutively- active or dominant negative) By timely, we mean that the clones are • Usually shipped within a day from when you place your order. Clones can be ordered from our web pages, by FAX or by phone. Within the United States, clones are shipped by overnight courier (FedEx); international orders are shipped International Priority (FedEx). The clones are supplied for research purposes only. Details on use of the material are included on the Material Transfer Agreement (page 3). Clones are distributed by agreement in Invitrogen's pcDNA3.1+ vector.
    [Show full text]
  • Characterisation, Localisation and Expression of Porcine TACR1, TACR2 and TACR3 Genes
    Veterinarni Medicina, 62, 2017 (08): 443–455 Original Paper doi: 10.17221/23/2017-VETMED Characterisation, localisation and expression of porcine TACR1, TACR2 and TACR3 genes A. Jakimiuk*, P. Podlasz, M. Chmielewska-Krzesinska, K. Wasowicz Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland *Corresponding author: [email protected] ABSTRACT: Substance P is involved in many physiological and pathophysiological processes. This functional diversity is mediated by three neurokinin receptor subtypes (NK1R, NK2R and NK3R) encoded by the TACR1, TACR2 and TACR3 genes, respectively. Despite the increasing interest in using pigs (Sus scrofa) to study human disease mechanisms, the sequences of these receptors are still unconfirmed or in the case of the NK1 receptor, not yet even unpredicted. We employed in silico analysis to define the localisation of the porcine tachykinin receptor genes, and to predict the structures and amino acid sequences of the respective proteins. A reverse transcription polymerase chain reaction (RT-PCR) assay was performed to analyse the expression of tachykinin receptor genes in different porcine tissues. The data show that the TACR1 gene is located on chromosome 3, TACR2 on chromo- some 14 and TACR3 on chromosome 8. All three genes encode proteins with structures that incorporate features of G-protein-coupled receptors with sizes of 407, 381 and 464 amino acids, respectively. The receptors display a high degree of similarity to other mammalian neurokinin receptors. The NK1R subtype is expressed in both the central nervous system and peripheral tissues, while NK2R expression seems to be localised mostly to peripheral tissues. The expression of NK3R is found mainly in the central nervous system.
    [Show full text]
  • (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation
    Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds.
    [Show full text]
  • Curcumin Alters Gene Expression-Associated DNA Damage, Cell Cycle, Cell Survival and Cell Migration and Invasion in NCI-H460 Human Lung Cancer Cells in Vitro
    ONCOLOGY REPORTS 34: 1853-1874, 2015 Curcumin alters gene expression-associated DNA damage, cell cycle, cell survival and cell migration and invasion in NCI-H460 human lung cancer cells in vitro I-TSANG CHIANG1,2, WEI-SHU WANG3, HSIN-CHUNG LIU4, SU-TSO YANG5, NOU-YING TANG6 and JING-GUNG CHUNG4,7 1Department of Radiation Oncology, National Yang‑Ming University Hospital, Yilan 260; 2Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung 40601; 3Department of Internal Medicine, National Yang‑Ming University Hospital, Yilan 260; 4Department of Biological Science and Technology, China Medical University, Taichung 404; 5Department of Radiology, China Medical University Hospital, Taichung 404; 6Graduate Institute of Chinese Medicine, China Medical University, Taichung 404; 7Department of Biotechnology, Asia University, Taichung 404, Taiwan, R.O.C. Received March 31, 2015; Accepted June 26, 2015 DOI: 10.3892/or.2015.4159 Abstract. Lung cancer is the most common cause of cancer CARD6, ID1 and ID2 genes, associated with cell survival and mortality and new cases are on the increase worldwide. the BRMS1L, associated with cell migration and invasion. However, the treatment of lung cancer remains unsatisfactory. Additionally, 59 downregulated genes exhibited a >4-fold Curcumin has been shown to induce cell death in many human change, including the DDIT3 gene, associated with DNA cancer cells, including human lung cancer cells. However, the damage; while 97 genes had a >3- to 4-fold change including the effects of curcumin on genetic mechanisms associated with DDIT4 gene, associated with DNA damage; the CCPG1 gene, these actions remain unclear. Curcumin (2 µM) was added associated with cell cycle and 321 genes with a >2- to 3-fold to NCI-H460 human lung cancer cells and the cells were including the GADD45A and CGREF1 genes, associated with incubated for 24 h.
    [Show full text]
  • An Evolutionary Based Strategy for Predicting Rational Mutations in G Protein-Coupled Receptors
    Ecology and Evolutionary Biology 2021; 6(3): 53-77 http://www.sciencepublishinggroup.com/j/eeb doi: 10.11648/j.eeb.20210603.11 ISSN: 2575-3789 (Print); ISSN: 2575-3762 (Online) An Evolutionary Based Strategy for Predicting Rational Mutations in G Protein-Coupled Receptors Miguel Angel Fuertes*, Carlos Alonso Department of Microbiology, Centre for Molecular Biology “Severo Ochoa”, Spanish National Research Council and Autonomous University, Madrid, Spain Email address: *Corresponding author To cite this article: Miguel Angel Fuertes, Carlos Alonso. An Evolutionary Based Strategy for Predicting Rational Mutations in G Protein-Coupled Receptors. Ecology and Evolutionary Biology. Vol. 6, No. 3, 2021, pp. 53-77. doi: 10.11648/j.eeb.20210603.11 Received: April 24, 2021; Accepted: May 11, 2021; Published: July 13, 2021 Abstract: Capturing conserved patterns in genes and proteins is important for inferring phenotype prediction and evolutionary analysis. The study is focused on the conserved patterns of the G protein-coupled receptors, an important superfamily of receptors. Olfactory receptors represent more than 2% of our genome and constitute the largest family of G protein-coupled receptors, a key class of drug targets. As no crystallographic structures are available, mechanistic studies rely on the use of molecular dynamic modelling combined with site-directed mutagenesis data. In this paper, we hypothesized that human-mouse orthologs coding for G protein-coupled receptors maintain, at speciation events, shared compositional structures independent, to some extent, of their percent identity as reveals a method based in the categorization of nucleotide triplets by their gross composition. The data support the consistency of the hypothesis, showing in ortholog G protein-coupled receptors the presence of emergent shared compositional structures preserved at speciation events.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • PROKR2 Gene Prokineticin Receptor 2
    PROKR2 gene prokineticin receptor 2 Normal Function The PROKR2 gene provides instructions for making a protein called prokineticin receptor 2. This receptor interacts with a protein called prokineticin 2 (produced from the PROK2 gene). On the cell surface, prokineticin 2 attaches to the receptor like a key in a lock. When the two proteins are connected, they trigger a series of chemical signals within the cell that regulate various cell functions. Prokineticin 2 and its receptor are produced in many organs and tissues, including the small intestine, certain regions of the brain, and several hormone-producing (endocrine) tissues. Prokineticin 2 and its receptor play a role in the development of a group of nerve cells that are specialized to process smells (olfactory neurons). These neurons move ( migrate) from the developing nose to a structure in the front of the brain called the olfactory bulb, which is critical for the perception of odors. Prokineticin 2 and its receptor are also involved in the migration of nerve cells that produce gonadotropin-releasing hormone (GnRH). GnRH controls the production of several hormones that direct sexual development before birth and during puberty. These hormones are also important for the normal function of the ovaries in women and the testes in men. Several additional functions of prokineticin 2 and its receptor have been discovered. These proteins help stimulate the movement of food through the intestine and are likely involved in the formation of new blood vessels (angiogenesis). They also play a role in coordinating daily (circadian) rhythms, such as the sleep-wake cycle and regular changes in body temperature.
    [Show full text]
  • WO 2019/068007 Al Figure 2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/068007 Al 04 April 2019 (04.04.2019) W 1P O PCT (51) International Patent Classification: (72) Inventors; and C12N 15/10 (2006.01) C07K 16/28 (2006.01) (71) Applicants: GROSS, Gideon [EVIL]; IE-1-5 Address C12N 5/10 (2006.0 1) C12Q 1/6809 (20 18.0 1) M.P. Korazim, 1292200 Moshav Almagor (IL). GIBSON, C07K 14/705 (2006.01) A61P 35/00 (2006.01) Will [US/US]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., C07K 14/725 (2006.01) P.O. Box 4044, 7403635 Ness Ziona (TL). DAHARY, Dvir [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (21) International Application Number: Box 4044, 7403635 Ness Ziona (IL). BEIMAN, Merav PCT/US2018/053583 [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (22) International Filing Date: Box 4044, 7403635 Ness Ziona (E.). 28 September 2018 (28.09.2018) (74) Agent: MACDOUGALL, Christina, A. et al; Morgan, (25) Filing Language: English Lewis & Bockius LLP, One Market, Spear Tower, SanFran- cisco, CA 94105 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/564,454 28 September 2017 (28.09.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/649,429 28 March 2018 (28.03.2018) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicant: IMMP ACT-BIO LTD.
    [Show full text]